LUPIN
500257Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015- ESG Rating
ESG Rating by Crisil ESG Ratings & Analytics Ltd.
Lupin Ltd is a globally integrated pharmaceutical company headquartered in Mumbai, India. Established in 1968, Lupin is renowned for developing, manufacturing, and marketing a diversified portfolio of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company serves markets across North America, India, Europe, Asia-Pacific, Latin America, Middle East, and Africa, with a strong presence in cardiovascular, anti-diabetic, respiratory, central nervous system, and ophthalmic therapies.
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015- ESG Rating
ESG Rating by Crisil ESG Ratings & Analytics Ltd.
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Intimation of allotment of 30967 equity shares under ESOP.
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating
ESG Rating by ESG Risk Assessment and Insights Limited.
Exclusive License Agreement With Visus Therapeutics, Inc. U.S.A.
VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.
Announcement under Regulation 30 (LODR)-Demise
Intimation of Demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Announces Approval from U.S. FDA for Pitolisant Tablets.
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Q1 FY2027 Earnings Conference Call
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation about participating in the Analyst/Institutional Investors Meet.
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of Newspaper publication in respect of Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Link of Audio recording of the Earnings Call-Q1 FY27.
Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation (Revised) - Q1 FY27 Results
Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation- Q1 FY2027
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Q1 FY2027 Results
Board Meeting Outcome For Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.
Board Meeting Outcome for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.
Board Meeting Outcome for Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.
Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Details of Voting Results of the Forty-Fourth Annual General Meeting along with the Consolidated Scrutinizer''s Report.
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the Forty-Fourth Annual General Meeting held on August 04, 2026.
Lupin Ltd
About
Lupin Ltd is a globally integrated pharmaceutical company headquartered in Mumbai, India. Established in 1968, Lupin is renowned for developing, manufacturing, and marketing a diversified portfolio of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company serves markets across North America, India, Europe, Asia-Pacific, Latin America, Middle East, and Africa, with a strong presence in cardiovascular, anti-diabetic, respiratory, central nervous system, and ophthalmic therapies.
Lupin has built a robust global footprint through a combination of research-driven innovation, strategic acquisitions, and operational excellence. The company operates 15 manufacturing sites and eight R&D centers worldwide and maintains a consistent focus on compliance and quality. Lupin’s continued emphasis on access to affordable medicines and leadership in generics has established it among the top pharmaceutical companies in India and a notable supplier to major regulated markets.
Business Model & Strategy
Lupin generates revenue through the development, production, and distribution of generic and branded pharmaceutical formulations, biosimilars, and APIs. Its core earnings are derived from export sales, predominantly to North America and Europe, while the India business provides strong domestic cash flows through a differentiated specialty and chronic therapy portfolio. The company sustains growth via organic pipeline additions, aggressive filings (ANDA, NDA, and biosimilars) in regulated markets, and expansion into complex generics, inhalation therapies, and specialty segments.
Strategic acquisitions and partnerships enable deeper access to developed and emerging markets, while investments in R&D foster a pipeline of differentiated products. Supply chain integration, cost efficiency, and compliance underpin its competitive strategy in both established and growth markets.
Management Overview
12 MembersMrs.Manju D. Gupta
Non-Executive - Non Independent Director-Chairperson related to PromoterMs.Vinita Gupta
Executive DirectorMr.Nilesh D. Gupta
Executive DirectorMr.Ramesh Swaminathan
Executive DirectorMr.Kanwar Bir Singh Anand
Non-Executive - Independent DirectorMs.Punita Kumar-Sinha
Non-Executive - Independent DirectorMr.Mark D. McDade
Non-Executive - Independent DirectorMr.Jeffrey Kindler
Non-Executive - Independent DirectorMr.Sunil Makharia
Interim Chief Financial OfficerMr.Alfonso Zulueta
Non-Executive - Independent DirectorMs.Punita Lal
Non-Executive - Independent DirectorMr.Amit Kumar Gupta
Company Secretary & Compliance OfficerAwards & Recognition
5 Awards- Included in Dow Jones Sustainability Emerging Markets Index 2024 for excellence in ESG practices
- Recipient of the 'Best Pharma Company of the Year' award at the Indian Pharma Awards 2024
- Recognized as a 'Top 10 Employer' in the Indian pharmaceutical sector by LinkedIn 2024
- Ranked among Forbes India's 'Super 50 Companies' 2024
- Awarded for 'Best Supply Chain in Pharma' at the Economic Times Supply Chain Summit 2025
Market Information
Company Timeline
57+ Years of Excellence | 10 Major Milestones
Lupin Ltd founded by Dr. Desh Bandhu Gupta in Mumbai, India
Entered US market with API exports
Launched first anti-TB fixed dose combination in India
Initial public offering (IPO) on NSE and BSE
Acquired Kyowa Pharmaceutical, Japan, marking Asian expansion
Acquired GAVIS Pharmaceuticals, strengthening US generics business
Expanded inhalation pipeline and biosimilar development
Launched generic Spiriva (Tiotropium) in US market
Achieved inclusion in Dow Jones Sustainability Index and expanded digital health initiatives
Awarded 'Best Pharma Company of the Year' and recognized among Forbes Super 50
The Next Evolution
Contact Information
Registered Office
Kalpataru Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East)
Tel: 022-66402402/ 66402403/ 66402323,
Fax: 022-26528806,
Email: investorservices@lupinpharma.com
Website: lupin.com
Corporate Actions
12| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Final Dividend ₹18 per share | 17 Jul 2026 Friday | 17 Jul 2026 Friday | - | - |
Final Dividend ₹12 per share | 25 Jul 2025 Friday | 25 Jul 2025 Friday | - | - |
Final Dividend ₹8 per share | 16 Jul 2024 Tuesday | 16 Jul 2024 Tuesday | - | - |
Final Dividend ₹4 per share | 14 Jul 2023 Friday | 14 Jul 2023 Friday | - | - |
Final Dividend ₹4 per share | 14 Jul 2022 Thursday | 15 Jul 2022 Friday | - | - |
Final Dividend ₹6.50 per share | 27 Jul 2021 Tuesday | 28 Jul 2021 Wednesday | - | - |
Final Dividend ₹6 per share | 03 Aug 2020 Monday | - | 05 Aug 2020 Wednesday | 12 Aug 2020 Wednesday |
Final Dividend ₹5 per share | 29 Jul 2019 Monday | - | 31 Jul 2019 Wednesday | 07 Aug 2019 Wednesday |
Dividend ₹5 per share | 30 Jul 2018 Monday | - | 01 Aug 2018 Wednesday | 08 Aug 2018 Wednesday |
Dividend ₹7.50 per share | 24 Jul 2017 Monday | - | 26 Jul 2017 Wednesday | 02 Aug 2017 Wednesday |
Dividend ₹7.50 per share | 25 Jul 2016 Monday | - | 27 Jul 2016 Wednesday | 03 Aug 2016 Wednesday |
Dividend ₹7.50 per share | 14 Jul 2015 Tuesday | - | 16 Jul 2015 Thursday | 23 Jul 2015 Thursday |
₹97,985 Cr.
₹2,150
₹2,530 / 1,875
17.71
₹492.38
4.35
₹121.01
₹2.00
0.84 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 17,082 | 15,859 | 15,299 | 16,547 | 16,715 | 20,131 | 22,904 | 28,382 | 30,442 |
| Expenses | - | - | - | 15,229 | 14,353 | 13,624 | 17,920 | 15,999 | 17,709 | 18,889 | 20,952 | 22,410 |
| Profit | - | - | - | 615 | -269.78 | 1,228 | -1,509.36 | 448 | 1,936 | 3,306 | 5,355 | 5,551 |
| Tax | - | - | - | 902 | 1,157 | 449 | 137 | 269 | 487 | 709 | 1,517 | 1,923 |
| EPS | - | - | - | 21 | -8.83 | 27 | -33.65 | 9 | 42 | 72 | 117 | 30.95 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 27,949 | 24,984 | 23,610 | 21,821 | 22,956 | 23,997 | 29,205 | 38,365 | - |
| Equity And Liabilities | - | - | - | 27,949 | 24,984 | 23,610 | 21,821 | 22,956 | 23,997 | 29,205 | 38,365 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 16 Apr '19 | Mar 2020 20 Apr '20 | Mar 2021 12 Apr '21 | Mar 2022 12 Apr '22 | Mar 2023 07 Apr '23 | Mar 2024 11 Apr '24 | Mar 2025 16 Apr '25 | Mar 2026 20 Apr '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | 0.28% | 0.28% | 0.29% | 0.29% | - | 0.01% | 0.01% | - | - |
| Promoter And Promoter Group | - | - | - | 46.97% | 46.92% | 46.86% | 46.78% | 47.08% | 47.01% | 46.92% | 46.86% | - |
| Non Institutions | - | - | - | 14.96% | 13.85% | 12.69% | 11.37% | 10.39% | 6.93% | 6.20% | 6.11% | - |
| FII | - | - | - | - | - | - | - | 13.32% | 18.28% | 21.46% | 21.71% | - |
| DII | - | - | - | - | - | - | - | 29.21% | 27.76% | 25.41% | 25.32% | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
Lupin Ltd
Lupin Ltd
Lupin Ltd is a globally integrated pharmaceutical company headquartered in Mumbai, India. Established in 1968, Lupin is renowned for developing, manufacturing, and marketing a diversified portfolio of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company serves markets across North America, India, Europe, Asia-Pacific, Latin America, Middle East, and Africa, with a strong presence in cardiovascular, anti-diabetic, respiratory, central nervous system, and ophthalmic therapies.
Lupin has built a robust global footprint through a combination of research-driven innovation, strategic acquisitions, and operational excellence. The company operates 15 manufacturing sites and eight R&D centers worldwide and maintains a consistent focus on compliance and quality. Lupin’s continued emphasis on access to affordable medicines and leadership in generics has established it among the top pharmaceutical companies in India and a notable supplier to major regulated markets.
Lupin generates revenue through the development, production, and distribution of generic and branded pharmaceutical formulations, biosimilars, and APIs. Its core earnings are derived from export sales, predominantly to North America and Europe, while the India business provides strong domestic cash flows through a differentiated specialty and chronic therapy portfolio. The company sustains growth via organic pipeline additions, aggressive filings (ANDA, NDA, and biosimilars) in regulated markets, and expansion into complex generics, inhalation therapies, and specialty segments.
Strategic acquisitions and partnerships enable deeper access to developed and emerging markets, while investments in R&D foster a pipeline of differentiated products. Supply chain integration, cost efficiency, and compliance underpin its competitive strategy in both established and growth markets.
Included in Dow Jones Sustainability Emerging Markets Index 2024 for excellence in ESG practices
Recipient of the 'Best Pharma Company of the Year' award at the Indian Pharma Awards 2024
Recognized as a 'Top 10 Employer' in the Indian pharmaceutical sector by LinkedIn 2024
Ranked among Forbes India's 'Super 50 Companies' 2024
Awarded for 'Best Supply Chain in Pharma' at the Economic Times Supply Chain Summit 2025
Lupin Ltd founded by Dr. Desh Bandhu Gupta in Mumbai, India
Entered US market with API exports
Launched first anti-TB fixed dose combination in India
Initial public offering (IPO) on NSE and BSE
Acquired Kyowa Pharmaceutical, Japan, marking Asian expansion
Acquired GAVIS Pharmaceuticals, strengthening US generics business
Expanded inhalation pipeline and biosimilar development
Launched generic Spiriva (Tiotropium) in US market
Achieved inclusion in Dow Jones Sustainability Index and expanded digital health initiatives
Awarded 'Best Pharma Company of the Year' and recognized among Forbes Super 50
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon